Vistagen Therapeutics Inc (VTGN) Director Purchases $15,220.80 in Stock
Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe bought 12,080 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average price of $1.26 per share, with a total value of $15,220.80. Following the completion of the purchase, the director now directly owns 3,251 shares in the company, valued at $4,096.26. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
NASDAQ VTGN traded down $0.01 on Friday, hitting $1.27. 495,452 shares of the company’s stock traded hands, compared to its average volume of 272,780. Vistagen Therapeutics Inc has a 1-year low of $0.81 and a 1-year high of $2.44. The stock has a market cap of $54.55 million, a price-to-earnings ratio of -1.14 and a beta of -0.34.
Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Tuesday, February 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). Sell-side analysts forecast that Vistagen Therapeutics Inc will post -0.9 earnings per share for the current fiscal year.
A number of research firms recently commented on VTGN. Maxim Group reiterated a “buy” rating and issued a $6.00 target price on shares of Vistagen Therapeutics in a research note on Wednesday, March 6th. ValuEngine cut shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $8.30.
WARNING: This article was reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.mareainformativa.com/news/2019/03/17/vistagen-therapeutics-inc-vtgn-director-purchases-15220-80-in-stock.html.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.